Atossa Therapeutics Inc (ATOS) Ganando

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 14 full-time employees. The company went IPO on 2012-11-08. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).